AU2009212373B2 - Non-polymeric compositions for controlled drug delivery - Google Patents

Non-polymeric compositions for controlled drug delivery Download PDF

Info

Publication number
AU2009212373B2
AU2009212373B2 AU2009212373A AU2009212373A AU2009212373B2 AU 2009212373 B2 AU2009212373 B2 AU 2009212373B2 AU 2009212373 A AU2009212373 A AU 2009212373A AU 2009212373 A AU2009212373 A AU 2009212373A AU 2009212373 B2 AU2009212373 B2 AU 2009212373B2
Authority
AU
Australia
Prior art keywords
acid
composition
bioactive substance
hormone
saib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009212373A
Other languages
English (en)
Other versions
AU2009212373A1 (en
AU2009212373A2 (en
Inventor
Benjamin Chien
Andrew Guarino
Yuhua Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foresee Pharmaceuticals Co Ltd
Original Assignee
Foresee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co Ltd filed Critical Foresee Pharmaceuticals Co Ltd
Publication of AU2009212373A1 publication Critical patent/AU2009212373A1/en
Publication of AU2009212373A2 publication Critical patent/AU2009212373A2/en
Assigned to FORESEE PHARMACEUTICALS, INC. reassignment FORESEE PHARMACEUTICALS, INC. Request for Assignment Assignors: QPS LLC
Application granted granted Critical
Publication of AU2009212373B2 publication Critical patent/AU2009212373B2/en
Assigned to FORESEE PHARMACEUTICALS CO., LTD. reassignment FORESEE PHARMACEUTICALS CO., LTD. Request for Assignment Assignors: FORESEE PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009212373A 2008-02-08 2009-02-05 Non-polymeric compositions for controlled drug delivery Ceased AU2009212373B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6517808P 2008-02-08 2008-02-08
US61/065,178 2008-02-08
PCT/US2009/033226 WO2009100222A1 (en) 2008-02-08 2009-02-05 Non-polymeric compositions for controlled drug delivery

Publications (3)

Publication Number Publication Date
AU2009212373A1 AU2009212373A1 (en) 2009-08-13
AU2009212373A2 AU2009212373A2 (en) 2011-02-17
AU2009212373B2 true AU2009212373B2 (en) 2013-10-03

Family

ID=40952458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009212373A Ceased AU2009212373B2 (en) 2008-02-08 2009-02-05 Non-polymeric compositions for controlled drug delivery

Country Status (8)

Country Link
US (1) US8586103B2 (enExample)
EP (1) EP2244679A4 (enExample)
JP (1) JP5737949B2 (enExample)
CN (1) CN102131483A (enExample)
AU (1) AU2009212373B2 (enExample)
CA (1) CA2714514C (enExample)
TW (1) TWI400090B (enExample)
WO (1) WO2009100222A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008143992A2 (en) 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
JP5718058B2 (ja) * 2008-02-08 2015-05-13 キューピーエス リミテッド ライアビリティ カンパニー タンパク質又はペプチドの徐放送達用組成物
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN102961362B (zh) * 2012-12-03 2014-07-30 上海应用技术学院 一种β-聚苹果酸/壳聚糖纳米药物缓释微胶囊及其制备方法
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP2986278A1 (en) 2013-03-11 2016-02-24 DURECT Corporation Injectable controlled release composition comprising high viscosity liquid carrier
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10034838B2 (en) 2014-09-10 2018-07-31 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs
WO2016046673A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
CN104721809A (zh) * 2015-03-12 2015-06-24 内蒙古金河动物药业有限公司 一种包含硫酸黏菌素的药物组合物及其制备方法
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
CN109069423A (zh) * 2016-03-07 2018-12-21 双键医药品股份公司 亲水性药物的肺部靶向递送
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations
US10668011B2 (en) * 2016-06-30 2020-06-02 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CN107173664A (zh) * 2017-04-27 2017-09-19 南昌大学 一种提高乳状液稳定性的没食子酸月桂酯复合抗氧化剂
AU2018383098B2 (en) 2017-12-11 2024-12-12 Tonix Pharma Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP3620494A1 (en) 2018-09-06 2020-03-11 Holland Novochem Technical Coatings B.V. Rheology modifier and compatibilizer
CN111388406B (zh) * 2020-03-24 2024-02-23 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
CN115666571B (zh) * 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
CN112806359B (zh) * 2020-12-30 2022-03-11 河北威远生物化工有限公司 一种生物可降解型农药缓释乳油及其制备方法和应用
CN115068414B (zh) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
EP4282435A1 (en) * 2022-05-23 2023-11-29 Danmarks Tekniske Universitet Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
US20060210599A1 (en) * 1995-06-07 2006-09-21 Gibson John W High viscosity liquid controlled delivery system and medical or surgical device
US20060228414A1 (en) * 2003-07-15 2006-10-12 Pr Phamaceuticals, Inc Method for the preparation of controlled release formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932610A (en) * 1971-12-06 1976-01-13 Lever Brothers Company Shampoo composition
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
DE69634277T2 (de) * 1995-06-07 2006-01-05 Southern Biosystems, Inc., Birmingham Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
JPH10218745A (ja) * 1997-02-12 1998-08-18 Rashieru Seiyaku Kk シャンプー組成物
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
EP1073419A4 (en) 1998-03-18 2009-03-25 Univ Technology Corp COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE.
ATE309822T1 (de) * 2000-04-19 2005-12-15 Genentech Inc Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
BRPI0515372B8 (pt) * 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210599A1 (en) * 1995-06-07 2006-09-21 Gibson John W High viscosity liquid controlled delivery system and medical or surgical device
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
US20060228414A1 (en) * 2003-07-15 2006-10-12 Pr Phamaceuticals, Inc Method for the preparation of controlled release formulations

Also Published As

Publication number Publication date
CA2714514A1 (en) 2009-08-13
CA2714514C (en) 2016-08-16
WO2009100222A1 (en) 2009-08-13
AU2009212373A1 (en) 2009-08-13
JP2011511088A (ja) 2011-04-07
TWI400090B (zh) 2013-07-01
EP2244679A4 (en) 2013-10-09
CN102131483A (zh) 2011-07-20
US20100034801A1 (en) 2010-02-11
AU2009212373A2 (en) 2011-02-17
US8586103B2 (en) 2013-11-19
EP2244679A1 (en) 2010-11-03
JP5737949B2 (ja) 2015-06-17
TW200936167A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CA2714514C (en) Non-polymeric compositions for controlled drug delivery
CA2714506C (en) Composition for sustained release delivery of proteins or peptides
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
AU2005271242B9 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
KR101466933B1 (ko) 펩타이드의 지속 방출 전달을 위한 의약 조성물
JP2011511088A5 (enExample)
JP2021516253A (ja) 選択された放出持続時間を有する医薬組成物
HK1162295A (en) Non-polymeric compositions for controlled drug delivery

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 JAN 2011

PC1 Assignment before grant (sect. 113)

Owner name: FORESEE PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): QPS LLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: FORESEE PHARMACEUTICALS CO., LTD.

Free format text: FORMER OWNER WAS: FORESEE PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired